Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Ellis

Showing results (121-130 of 285) with videos related to

Pageof 29
Sort By:
Cancer Discovery|October 15, 2013
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis ConsortiumMatthew J Ellis, Michael Gillette, Steven A Carr, et al.
Cancer Research|October 16, 2003
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression statusMatthew J Ellis, Andrew Coop, Baljit Singh, et al.
Critical Care Medicine|February 21, 2015
Detailed characterization of a long-term rodent model of critical illness and recoveryNeil E Hill, Saima Saeed, Rahul Phadke, et al.
Breast Cancer Research and Treatment|April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancerCynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Breast Cancer Research and Treatment|July 4, 2021
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei-Yin C Polley, Maura N Dickler, Jason Sinnwell, et al.
The Lancet. Oncology|November 19, 2013
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trialAman U Buzdar, Vera J Suman, Funda Meric-Bernstam, et al.
Journal of the National Cancer Institute|September 25, 2008
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristicsMatthew J Ellis, Yu Tao, Jingqin Luo, et al.
Molecular & Cellular Proteomics : MCP|August 11, 2018
gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics DataAlexander B Saltzman, Mei Leng, Bhoomi Bhatt, et al.
Breast Cancer Research and Treatment|February 19, 2009
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical careChristopher L Tebbit, Jun Zhai, Brian R Untch, et al.
The New England Journal of Medicine|August 20, 2004
Circulating tumor cells, disease progression, and survival in metastatic breast cancerMassimo Cristofanilli, G Thomas Budd, Matthew J Ellis, et al.
Pageof 29

Showing results (121-130 of 285) with videos related to

Sort By:
Pageof 29
Cancer Discovery|October 15, 2013
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis ConsortiumMatthew J Ellis, Michael Gillette, Steven A Carr, et al.
Cancer Research|October 16, 2003
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression statusMatthew J Ellis, Andrew Coop, Baljit Singh, et al.
Critical Care Medicine|February 21, 2015
Detailed characterization of a long-term rodent model of critical illness and recoveryNeil E Hill, Saima Saeed, Rahul Phadke, et al.
Breast Cancer Research and Treatment|April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancerCynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Breast Cancer Research and Treatment|July 4, 2021
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei-Yin C Polley, Maura N Dickler, Jason Sinnwell, et al.
The Lancet. Oncology|November 19, 2013
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trialAman U Buzdar, Vera J Suman, Funda Meric-Bernstam, et al.
Journal of the National Cancer Institute|September 25, 2008
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristicsMatthew J Ellis, Yu Tao, Jingqin Luo, et al.
Molecular & Cellular Proteomics : MCP|August 11, 2018
gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics DataAlexander B Saltzman, Mei Leng, Bhoomi Bhatt, et al.
Breast Cancer Research and Treatment|February 19, 2009
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical careChristopher L Tebbit, Jun Zhai, Brian R Untch, et al.
The New England Journal of Medicine|August 20, 2004
Circulating tumor cells, disease progression, and survival in metastatic breast cancerMassimo Cristofanilli, G Thomas Budd, Matthew J Ellis, et al.
Pageof 29